Stay up to date on all things heart attack. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Share this post on your profile with a comment of your own:

Successfully Shared!

View on my Profile

CLEAR SYNERGY Neutrophil Substudy

June 11, 2019



CLEAR SYNERGY is an international, randomized placebo controlled trial of the poisonous alkaline colchicine and antagonist treatment of spironolactone in patients with a history of a heart attack(s). Blood is drawn from the participants initially and at a 3 months follow-up. They will have an also have an additional 2 tablespoons of blood drawn.


The sub study objectives are to:


  • Assess the effect of colchicine on neutrophil activation in response to heart attacks.
  • Examine clinical and genetic factors that determine heterogeneity of treatment response and distinguish colchicine responders from people who don’t respond.
  • Explore the derivation of a risk score that includes markers of neutrophil activity and is associated with adjudicated MACE, an endpoint or cardiovascular research, over 3 years after the heart attacks, and assess the impact of colchicine on the relation between this risk score and MACE.


Study Information


This is an observational study that began on March 4, 2019 and is estimated to be completed by February 1, 2021. This is an estimated 670 participants.


Inclusion Criteria


  • All sexes, ages 19 to 110 years old
  • Patients who are randomized to the drug RCT portion of the CLEAR SYNERGY (OASIS 9) trial will be eligible for participation in this Neutrophil biomarker substudy.


Exclusion Criteria


  • Use of anti-inflammatory agents (except aspirin)
  • Active infection




You may participate in this study at NYU School of Medicine in New York, New York, United States, 10016. If you have any questions please contact Fatmira Curovic at 646-501-9648 or at You may also contact Binita Shah, MD.




This study is sponsored by NYU Langone Health, the Population Health Research Institute, the National Heart, Lung, and Blood Institute (NHLBI). Binita Shah, MD, from NYU School of Medicine will serve as the Principal Investigator.

Clinical Trials

View All

Testing a Community Intervention to Increase Aspirin Use

Recently, there is a growing consensus that aspirin, when appropriately used, reduces cardiovascular death in men,…

MRI of Myocardial Infarction

Heart failure (HF) affects approximately 5.1 million people in the US and is the cause of 250,000 deaths each year.…

Impact of Daylight on Patients With Acute Myocardial Infarction

Damage from a heart attack usually occurs during the early morning hours. Therefore, the circadian system is…

Evaluating Vitamin D Normalization on Cardiovascular-Related Events

This study evaluates whether achieving 25-hydroxyvitamin D, or  25[OH] Vit D (what vitamin D is converted into…

The Impact of Early Follow-up on Readmission Rates in AMI Patients

This study aims to conduct the first randomized, prospective trial to better clear up the association between early…

Testosterone Replacement and Exercise Capacity in Hypogonadal Men

This study examines the effect of testosterone replacement on the ability to exercise for men with functional…

Women’s Heart Attack Research Program

This clinical trial examines a higher than normal number of platelets, Review Trial

Send this to a friend